article Open AccessTop 1% cited
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Clinical Cancer Research · 2007 · Vol. 13(4) · pp. 1253–1259
James J. Vredenburgh✉(Immunovaccine (Canada))Annick Desjardins(Immunovaccine (Canada))James E. Herndon(Biostatistical Consulting (United States))Jeannette M. Dowell(Cancer Research And Biostatistics)David A. Reardon(Pediatrics and Genetics)Jennifer A. Quinn(Immunovaccine (Canada))Jeremy N. Rich(Institute of Neurobiology)Sith Sathornsumetee(Immunovaccine (Canada))Sridharan Gururangan(Pediatrics and Genetics)Melissa WagnerDarell D. Bigner(Duke Medical Center)Allan H. FriedmanHenry S. Friedman(Pediatrics and Genetics)
Abstract
The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity.
Glioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismBrain Metastases and TreatmentMedicineBevacizumabIrinotecanGliomaSurgeryInternal medicineChemotherapyGastroenterologyCancerColorectal cancer
MeSH terms
BevacizumabIrinotecanAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCamptothecinFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective Studies
Citations
1,074
FWCI
56.71
field-weighted impact
References
49
Percentile
100%
vs. same field & year
Citations per year
Cited by
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Oncotarget · 2017 · 415 citations
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Journal of Clinical Oncology · 2009 · 2,431 citations
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
The Lancet Oncology · 2009 · 7,709 citations
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Development · 2007 · 2,299 citations
References
Angiogenesis in cancer and other diseases
Nature · 2000 · 8,970 citations
Response criteria for phase II studies of supratentorial malignant glioma.
Journal of Clinical Oncology · 1990 · 2,400 citations
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
British Journal of Cancer · 2000 · 935 citations
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
Cancer Research · 2004 · 1,179 citations
The biology of VEGF and its receptors
Nature Medicine · 2003 · 9,519 citations
Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials
JNCI Journal of the National Cancer Institute · 1993 · 1,304 citations
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
New England Journal of Medicine · 2005 · 21,276 citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine · 2004 · 10,930 citations
Related articles
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Journal of Clinical Oncology · 2009 · 2,431 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.